SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Qu, C.-K. Articles by Feng, G.-S. Search for Related Content PubMed PubMed Citation Articles by Qu, C.-K. Articles by Feng, G.-S. Related Collections Hematopoiesis and Stem Cells Immunobiology Signal Transduction Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 February 2001, Vol. 97, No. 4, pp. 911-914 HEMATOPOIESIS Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development Cheng-Kui Qu, Suzanne Nguyen, Jianzhu Chen, and Gen-Sheng Feng From the Burnham Institute, La Jolla, CA; Department of Biochemistry and Molecular Biology, Walther Oncology Center, Indiana University School of Medicine, Indianapolis, IN; and Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA.     Abstract Top Abstract Introduction Materials and methods Results and discussion References Shp-1 and Shp-2 are cytoplasmic phosphotyrosine phosphatases with similar structures. Mice deficient in Shp-2 die at midgestation with defects in mesodermal patterning, and a hypomorphic mutation at the Shp-1 locus results in the moth-eaten viable (mev) phenotype. Previously, a critical role of Shp-2 in mediating erythroid/myeloid cell development was demonstrated. By using the RAG-2-deficient blastocyst complementation, the role of Shp-2 in lymphopoiesis has been determined. Chimeric mice generated by injecting Shp-2/ embryonic stem cells into Rag-2-deficient blastocysts had no detectable mature T and B cells, serum immunoglobulin M, or even Thy-1+ and B220+ precursor lymphocytes. Collectively, these results suggest a positive role of Shp-2 in the development of all blood cell lineages, in contrast to the negative effect of Shp-1 in this process. To determine whether Shp-1 and Shp-2 interact in hematopoiesis, Shp-2/:mev/mev double-mutant embryos were generated and the hematopoietic cell development in the yolk sacs was examined. More hematopoietic stem/progenitor cells were detected in Shp-2/:mev/mev embryos than in Shp-2/ littermates. The partial rescue by Shp-1 deficiency of the defective hematopoiesis caused by the Shp-2 mutation suggests that Shp-1 and Shp-2 have antagonistic effects in hematopoiesis, possibly through a bidirectional modulation of the same signaling pathway(s). (Blood. 2001;97:911-914) © 2001 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results and discussion References Shp-1 and Shp-2 compose a small subfamily of protein tyrosine phosphatases that are distinguished by possession of Src-homology 2 domains.1-3 Shp-2 is a widely expressed enzyme in contrast to Shp-1, which is predominantly expressed in hematopoietic and lymphoid cells. Thus, these 2 phosphatases coexist in blood cell lineages. In the past few years, experimental results from a number of laboratories have indicated critical roles of Shp-1 and Shp-2 in the modulation of signaling events in various types of blood cells, in a positive or a negative fashion.2,4,5 However, several important issues remain to be addressed. First, although Shp-2 was shown to be required for erythroid/myeloid cell differentiation, it is unclear whether Shp-2 plays a critical role in lymphocyte development. In previous experiments, we created a targeted mutant Shp-2 allele by deleting exon 3, which results in embryonic lethality at midgestation in homozygotes.6 In vitro hematopoietic differentiation assay of Shp-2/ embryonic stem (ES) cells showed a severe suppression of erythroid/myeloid progenitor cell development by the Shp-2 mutation.7 Consistently, neither erythroid nor myeloid progenitor cells of Shp-2/ origin were detectable in the fetal liver or bone marrow of chimeric animals that were derived from aggregation of Shp-2/ ES cells and wild-type embryos, despite a significant contribution of Shp-2/ cells to quite a few tissues of the chimeras.8 These observations suggest a stringent requirement of a functional Shp-2 for erythroid/myeloid cell development. However, a specific role of Shp-2 phosphatase in lymphocyte development remains to be established. This is clearly important for identifying the acting point of Shp-2 in the hierarchy of stem/progenitor cell differentiation into erythroid, myeloid, and lymphoid cell lineages. Second, moth-eaten (me) and moth-eaten viable (meV) mice that contain spontaneous mutations in the Shp-1 gene9,10 are characterized by immunodeficiency, autoimmunity, and augmented production and tissue infiltration of granulocytes, macrophages, and lymphocytes as well as excessive erythropoiesis.4,11 Thus, Shp-1 is primarily a negative effector in hematopoietic cell development and function, as compared with Shp-2, which has been implicated as both a negative and positive regulator in lymphocyte signaling.4,12,13 Because Shp-1 and Shp-2 are coexpressed in hematopoeitic cells, it is unclear whether they interact or even have antagonistic effects in hematopoiesis. This study was initiated with the goal of addressing these 2 questions. First, we examined the specific requirement of Shp-2 for lymphocyte development using the Rag-2-deficient blastocyst complementation. Second, we investigated the functional interaction of Shp-1 and Shp-2 using a genetic approach by generating double-mutant embryos and analyzing the effect of the double Shp-1/Shp-2 mutations on hematopoiesis. Our findings suggest that Shp-2 is required for lymphopoiesis and that Shp-1 and Shp-2 have antagonistic effect in hematopoiesis.     Materials and methods Top Abstract Introduction Materials and methods Results and discussion References Generation of Shp-2//Rag-2/ chimeric mice Rag-2-deficient mice were maintained in a pathogen-free facility, and 4- to 8-week-old females were used as blastocyst donors. Rag-2/ blastocysts were recovered from the uterus of 3.5-day postcoitum pregnant females, and Shp-2+/ and Shp-2/ ES cells were injected into Rag-2/ blastocysts as described.14,15 Injected embryos were then transferred into the uterus of synchronized pseudopregnant foster mothers. After pups were born, chimeric mice were identified by agouti coat color and by polymerase chain reaction (PCR) assaying for the Shp-2 mutant allele in the tail DNA.8 Flow cytometry analysis Chimeric mice (6 weeks old) generated from Shp-2+/ or Shp-2/ ES cells were euthanized. Spleen, thymus, and bone marrow cells were assayed by flow cytometry using conjugated antibodies specific to CD4, CD8, CD19, immunoglobulin (Ig) M, Thy-1, B220, and Ly9.1 (Pharmingen, San Diego, CA). Stained cells were analyzed on a Beckman FACScan, and live cells were collected and analyzed. Generation of Shp-2, Shp-1 double-mutant mice Heterozygous meV mice (C57BL/6J-Hcphme-v/+) were purchased from the Jackson Laboratory (Bar Harbor, ME). These mice were crossed with Shp-2+/ mice, and double-heterozygous (mev/+:Shp-2+/) mutant mice were identified from the F1 offspring by PCR detection of wild-type and mutant alleles of Shp-2 and Shp-1 in tail DNA as described.8,16 Double- homozygous (mev/mev:Shp-2/) and single-homozygous (mev/mev or Shp-2/) embryos were generated by intercrossing mev/+:Shp-2+/ mutant mice. Hematopoietic progenitor assay Embryos at days 9.0 to 9.5 from the intercrosses between mev/+: Shp-2+/ mice were dissected. Yolk sacs were carefully separated from the embryos in -minimal essential medium (-MEM) supplemented with 15% fetal calf serum and dissociated to single-cell suspension by passing through a 22-gauge needle as described previously.8 Yolk sac cells were plated into a colony-forming unit (CFU)-assay system, which contains -MEM, 30% fetal calf serum, 5% pokeweed mitogen-stimulated mouse spleen cell-conditioned medium, erythropoietin (2 U/mL EPO; Amgen, Thousand Oaks, CA), murine stem cell factor (50 ng/mL; Immunex, Seattle, WA), glutamine (104 M), -mercaptoethanol (3.3 × 105 M), hemin (100 µm; Eastman Kodak, Rochester, NY), and 0.9% methylcellulose. CFU-assay cultures were incubated at 37°C in a 5% CO2 moisture-saturated incubator. After 6 to 7 days, colonies from erythroid burst-forming unit (BFU-E), granulocyte-macrophage (CFU-GM), and multipotential (CFU-granulocyte, erythroid, macrophage, megakaryocyte, or CFU-GEMM) progenitors were s cored.8,17     Results and discussion Top Abstract Introduction Materials and methods Results and discussion References Block of T- and B-lymphocyte development by the Shp-2 mutation Our previous work showed that Shp-2 is required for erythroid and myeloid cell differentiation.7,8 To determine the role of Shp-2 in lymphocyte development, we employed the Rag-2-deficient blastocyst complementation assay.14,18 Shp-2+/ or Shp-2/ ES cells were injected into Rag-2/ blastocysts to generate chimeric animals. Because Rag-2/ mice do not produce any T and B lymphocytes because of the inability to initiate V(D)J recombination, any mature T and B lymphocytes detected in the chimeras must be derived from injected ES cells. Splenocytes and thymocytes from RAG/ mice or chimeras generated from Shp-2+/ or Shp-2/ ES cells were stained for CD4 and CD8 and then analyzed by flow cytometry. In Shp-2+//Rag-2/ chimeras, CD4+ or CD8+ mature T cells were readily detected in the spleen, and CD4+, CD8+, and CD4+CD8+ cells were detected in the thymus (Figure 1). Although there were some CD4+ cells in the spleen of Shp-2//Rag-2/ chimeras, the staining profile was the same as in Rag-2/ mice. Like Rag-2/ mice, there were no CD4, CD8 single-positive cells or CD4 and CD8 double-positive cells in the thymus of Shp-2//Rag-2/ chimeras. Staining of splenocytes with CD19 and IgM revealed the presence of CD19+IgM+ mature B cells in Shp-2+//Rag-2/ chimeras, whereas there were only few CD19+ precursor B cells in Shp-2//Rag-2/ chimeras or Rag-2/ mice (Figure 1). Consistently, serum IgM, which is a more sensitive indication of the presence of mature B cells, was not detected by enzyme-linked immunosorbent assay in all 11 chimeric mice generated from Shp-2/ ES cells (data not shown). View larger version (37K): [in this window] [in a new window]   Figure 1. Shp-2 is required for T- and B-lymphocyte development. Thymocytes or splenocytes were stained with anti-CD4 and anti-CD8a; splenocytes were also stained with anti-IgM and anti-CD19. Live cells (10 000) were collected and analyzed for each sample. Data from one Shp-2+//Rag-2/ and one Shp-2//Rag-2/ chimera are shown. We examined 4 Shp-2//Rag-2/ chimeric animals and obtained consistent results. To determine the stage of lymphocyte development that was blocked by the Shp-2 mutation, ES cell-derived precursor T cells in the thymus and precursor B cells in the bone marrow were assayed by staining for Thy-1 plus Ly-9.1 or B220 plus Ly-9.1, respectively. Ly-9.1 staining was able to distinguish the ES and blastocyst-derived precursor lymphocytes because the R1 ES cell line used for Shp-2 targeting was derived from 129/sv strain of mouse and therefore was Ly-9.1+, whereas blastocyst-derived cells were Ly-9.1. As shown in Figure 2, Thy-1+Ly-9.1+ T-lineage cells and B220+Ly-9.1+ B-lineage cells were detected in the thymus and bone marrow, respectively, in chimeras generated with Shp-2+/ ES cells. In contrast, no Thy-1+Ly-9.1+ T-lineage cells were detected in the thymus, and no B220+Ly-9.1+ B-lineage cells were detected in bone marrow cells of Shp-2//Rag-2/ chimeric mice. Together, these data suggest that the Shp-2 mutation causes a block of lymphocyte development at a very early stage, even before precursor T and B cells. View larger version (36K): [in this window] [in a new window]   Figure 2. The Shp-2 mutation blocks lymphopoiesis at the precursor stage. Thymocytes were stained with anti-LY9.1 and anti-THY-1, and bone marrow cells were stained with anti-LY9.1 and anti-B220 and analyzed by flow cytometry. Results from one Shp-2+//Rag-2/ and one Shp-2//Rag-2/ chimera are shown. Four Shp-2//Rag-2/ chimeric animals were examined, and consistent results were obtained. The failure to detect the ES cell-derived lymphocytes in Shp-2//Rag-2/ chimeras was not due to an inability to generate chimeric mice. First, chimerism was assayed by PCR analysis of tail DNA and was shown by the presence of the Shp-2 mutant allele (Figure 3A). Second, Southern blot analysis clearly detected the Shp-2 mutant allele in nonlymphoid lineage cells in the thymus, spleen, and bone marrow of Shp-2+//Rag-2/ or Shp-2//Rag-2/ chimeric animals, indicating a reasonable contribution by mutant ES cells (Figure 3B). Third, all Shp-2//Rag-2/ chimeras, as determined by PCR, had kinky tails, a trait not seen in nonchimeras or chimeras generated from Shp-2+/ ES cells (Figure 3C). This phenotype was observed previously in Shp-2//wild-type chimeric mice. The kinky tail phenotype was also observed in targeted mutant mice lacking fibroblast growth factor receptor-3, due to enhanced and prolonged endochondral bone growth accompanied by expansion of proliferating and hypertrophic chondrocytes within the cartilaginous growth plate.19 Shp-2 phosphatase is required for the full and sustained activation of Erk kinase induced by fibroblast growth factor receptor-1.6 Collectively, these data suggest that the Shp-2 mutation has different effects on the development of various cell types: It is required for early lymphopoiesis and is involved in mediating the development of hypertrophic chondrocytes. View larger version (91K): [in this window] [in a new window]   Figure 3. Detection of chimerism. (A) PCR analysis of tail DNA. To detect the contribution of Shp-2/ ES cells to the body of chimeric animals, tail DNA was extracted from Shp-2//Rag-2/ chimeras as well as one Rag-2/ animal as a control. Detection of wild-type (wt) and mutant (mt) Shp-2 alleles was done by PCR analysis. (B) Southern blot analysis of DNA extracted from bone marrow, thymus, and spleen of Shp-2+//Rag-2/ or Shp-2//Rag-2/ chimeras. Wild-type and mutant Shp-2 alleles were detected using a specific probe as described previously.8 (C) One Rag-2/ animal (left) and 3 Shp-2//Rag-2/ chimeric mice with kinky tail are shown. Shp-1 mutation partially rescues the hematopoietic defects caused by Shp-2 mutation The results described above, together with our previous observations that the Shp-2 mutation suppressed erythroid/myeloid cell differentiation, suggest an important role of Shp-2 in the development of all blood cell lineages. To determine if there is any functional interaction between Shp-1 and Shp-2 in hematopoiesis, we generated double-mutant animals by crossing Shp-2+/ mice with meV/+ mice. Double-mutant mice (Shp-2/:meV/meV) also died at midgestation with a phenotype similar to Shp-2/ embryos, having multiple defects in the mesodermal induction and body organization, particularly the posterior truncation, as described previously.6 Hematopoietic activity was assessed by detecting stem/progenitor cells from the yolk sacs using the CFU assay. As shown in Figure 4, hematopoietic cell development was dramatically suppressed in Shp-2/ yolk sacs, consistent with the previous result.8 Interestingly, an additional homozygous mutation at the Shp-1 locus partially complemented the hematopoietic defect caused by the Shp-2 mutation. Higher numbers of erythroid lineage (BFU-E) and mixed erythroid-myeloid lineage (CFU-GEMM) progenitors were detected in the double-mutant yolk sacs than in Shp-2/ littermates. This result suggests an antagonistic effect between Shp-1 and Shp-2 in the development of blood cells, the cell type in which both are normally expressed. View larger version (28K): [in this window] [in a new window]   Figure 4. Antagonistic effect of Shp-1 and Shp-2 in mediating embryonic hematopoiesis. Yolk sacs at 9.0 to 9.5 days postcoitum from intercrosses between mev/+:Shp-2+/ mice were carefully dissected free of maternal tissues in -MEM supplemented with 15% fetal calf serum. Single-cell suspension was prepared by passing through a 22-gauge needle. Cells were washed once in -MEM and plated for CFU assay. Genotyping: 1. Shp-2/:+/+ or mev/+; 2. Shp-2/:mev/mev; 3. Shp-2+/+,+/:mev/mev; 4. Shp-2+/+,+/:+/+, mev/+. The results were summarized from 5 independent experiments. There was a significant difference between Shp-2/:+/+ or mev/+ and Shp-2/:mev/mev mice for BFU-E and CFU-GEMM (P = .03, t test). As a widely expressed enzyme, the involvement of Shp-2 in cytoplasmic signaling has been demonstrated in a variety of cell types. Shp-2 phosphatase has been implicated as a negative or a positive regulator in different signaling pathways.2 Introduction of a targeted mutation at a tyrosine phosphorylation site (Y759F) in gp130, a coreceptor for interleukin-6 family cytokines, resulted in splenomegaly, lymphadenopathy, and an enhanced acute phase reaction in mutant mice.20 Because Shp-2 binds to phosphorylated Y759, it was reasonable to speculate that Shp-2 acts to negatively regulate the development of T, B, and myeloid cells. However, a more recent report indicates that this tyrosine residue at gp130 is also a docking site for suppressor of cytokine signaling-3 (SOCS-3) and, therefore, the negative regulatory roles previously attritbuted to Shp-2 might be mediated, at least in part, by SOCS-3.21 Using the Rag-2-deficient blastocyst complementation, we have now clearly demonstrated a requirement of Shp-2 for lymphopoiesis in a cell-autonomous manner. Differentiation of lymphoid cell lineages in Shp-2//Rag-2/ chimeric mice was blocked before pro-T- and pro-B-cell stages. In combination with our previous observations,7,8 our data indicate that Shp-2 is required for the development of erythroid, myeloid, and lymphoid cell lineages. This is consistent with previous data demonstrating a defective expression of PU.1 and interleukin-7 receptor, critical genes for lymphocytes and other cell types, in embryoid bodies differentiated from Shp-2/ ES cells.7 The block to all blood cell lineages by the Shp-2 mutation strongly suggests that Shp-2 has a role in hematopoietic stem/progenitor cell commitment and differentiation at a very early stage. However, our observation does not rule out the possibility that Shp-2 also has other functions, negative or positive, at later stages of hematopoiesis or in the activities of terminally differentiated myeloid/lymphoid cells. Insight into these aspects of Shp-2 function will be provided by generating conditional Shp-2 knockout alleles in a specific cell lineage at given developmental stages. Whether Shp-1 and Shp-2 have functional interactions was not clear, although their physiologic roles are at least not completely redundant, because the defective phenotype caused by the Shp-1 mutation was not complemented by the normal expression of Shp-2 in moth-eaten mice.1 Notably, one recent study identified an activity shared by Shp-1 and Shp-2 in mediating the inhibitory signal relay from paired Ig-like receptor B (PIR-B) in B lymphocytes.22 In contrast, we present evidence here that Shp-1 and Shp-2 have antagonistic effects in mediating embryonic hematopoiesis. The defective yolk sac hematopoiesis caused by the Shp-2 mutation was partially rescued by an additional Shp-1 mutation. This finding will help to elucidate the cytoplasmic signaling events mediated by Shp-1 and Shp-2 in hematopoiesis and possibly leukemogenesis.     Acknowledgments We thank Dr M. Boes for performing the IgM enzyme-linked immunosorbent assay and W. M. Yu for technical assistance.     Footnotes Submitted August 9, 2000; accepted October 20, 2000. Supported by grants from National Institutes of Health (CA78606 and GM53660 to G.-S.F. and AI40146 and AI 44478 to J.C.). The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Gen-Sheng Feng, The Burnham Institute, 10901 N Torrey Pines Rd, La Jolla, CA 92037; e-mail: gfeng{at}burnham-inst.org.     References Top Abstract Introduction Materials and methods Results and discussion References 1. Feng GS, Pawson T. Phosphotyrosine phosphatases with SH2 domains: regulators of signal transduction. Trends Genet. 1994;10:54-58[CrossRef][Medline] [Order article via Infotrieve]. 2. Feng GS. Shp-2 tyrosine phosphatase: signaling one cell or many. Exp Cell Res. 1999;253:47-54[CrossRef][Medline] [Order article via Infotrieve]. 3. Neel BG. Structure and function of SH2-domain containing tyrosine phosphatases. Semin Cell Biol. 1993;4:419-432[CrossRef][Medline] [Order article via Infotrieve]. 4. Siminovitch KA, Neel BG. Regulation of B cell signal transduction by SH2-containing protein-tyrosine phosphatases. Semin Immunol. 1998;10:329-347[CrossRef][Medline] [Order article via Infotrieve]. 5. Scharenberg AM, Kinet JP. The emerging field of receptor-mediated inhibitory signaling: SHP or SHIP? Cell. 1996;87:961-964[CrossRef][Medline] [Order article via Infotrieve]. 6. Saxton TM, Henkemeyer M, Gasca S, et al. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. EMBO J. 1997;16:2352-2364[CrossRef][Medline] [Order article via Infotrieve]. 7. Qu CK, Shi ZQ, Shen R, Tsai FY, Orkin SH, Feng GS. A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development. Mol Cell Biol. 1997;17:5499-5507[Abstract]. 8. Qu CK, Yu WM, Azzarelli B, Cooper S, Broxmeyer HE, Feng GS. Biased suppression of hematopoiesis and multiple developmental defects in chimeric mice containing Shp-2 mutant cells. Mol Cell Biol. 1998;18:6075-6082[Abstract/Free Full Text]. 9. Tsui HW, Siminovitch KA, de Souza L, Tsui FW. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat Genet. 1993;4:124-129[CrossRef][Medline] [Order article via Infotrieve]. 10. Shultz LD, Schweitzer PA, Rajan TV, et al. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell. 1993;73:1445-1454[CrossRef][Medline] [Order article via Infotrieve]. 11. Tsui FW, Tsui HW. Molecular basis of the motheaten phenotype. Immunol Rev. 1994;138:185-206[CrossRef][Medline] [Order article via Infotrieve]. 12. Marengere LE, Waterhouse P, Duncan GS, Mittrucker HW, Feng GS, Mak TW. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science. 1996;272:1170-1173[Abstract]. 13. Lee KM, Chuang E, Griffin M, et al. Molecular basis of T cell inactivation by CTLA-4. Science. 1998;282:2263-2266[Abstract/Free Full Text]. 14. Chen J, Lansford R, Stewart V, Young F, Alt FW. Rag-2-deficient blastocyst complementation: an assay of gene function in lymphocyte development. Proc Natl Acad Sci U S A. 1993;90:4528-4532[Abstract/Free Full Text]. 15. Chen J, Shinkai Y, Young F, Alt FW. Probing immune functions in RAG-deficient mice. Curr Opin Immunol. 1994;6:313-319[CrossRef][Medline] [Order article via Infotrieve]. 16. Kim CH, Qu CK, Hangoc G, et al. Abnormal chemokine-induced responses of immature and mature hematopoietic cells from motheaten mice implicate the protein tyrosine phosphatase SHP-1 in chemokine responses. J Exp Med. 1999;190:681-690[Abstract/Free Full Text]. 17. Cooper S, Broxmeyer HE. Measurement of interleukin-3 and other hematopoietic growth factors, such as GM-CSF, G-CSF, M-CSF, erythropoietin and the other potent co-stimulating cytokines steel factor and Flt-3 ligand. Curr Protocols Immunol. 1996;18(suppl):6.4.1-6.4.12. 18. Chen J. Analysis of gene function in lymphocytes by Rag-2-deficient blastocyst complementation. Adv Immunol. 1996;62:31-59[Medline] [Order article via Infotrieve]. 19. Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell. 1996;84:911-921[CrossRef][Medline] [Order article via Infotrieve]. 20. Ohtani T, Ishihara K, Atsumi T, et al. Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3- and SHP2-mediated signals in immune responses. Immunity. 2000;12:95-105[CrossRef][Medline] [Order article via Infotrieve]. 21. Nicholson SE, De Souza D, Fabri LJ, et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci U S A. 2000;97:6493-6498[Abstract/Free Full Text]. 22. Maeda A, Kurosaki M, Ono M, Takai T, Kurosaki T. Requirement of SH2-containing protein tyrosine phosphatases SHP-1 and SHP-2 for paired immunoglobulin-like receptor B (PIR-B)-mediated inhibitory signal. J Exp Med. 1998;187:1355-1360[Abstract/Free Full Text]. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Wang, W.-M. Yu, W. Zhang, K. R. McCrae, B. G. Neel, and C.-K. Qu Noonan Syndrome/Leukemia-associated Gain-of-function Mutations in SHP-2 Phosphatase (PTPN11) Enhance Cell Migration and Angiogenesis J. Biol. Chem., January 9, 2009; 284(2): 913 - 920. [Abstract] [Full Text] [PDF] Mei Feng, Ruopeng Sun, Chengmei Zhang, Enhua Sun, Shaochun Wei, Jiaqing Wan, and Ruopeng Sun Increased Expression of Tyrosine Phosphatase SHP2 in Experimental Pneumococcal Meningitis: Correlation With Tumor Necrosis Factor-Alpha and Cerebrospinal Fluid Pleocytosis J Child Neurol, March 1, 2008; 23(3): 287 - 292. [Abstract] [PDF] N. Ohnishi, H. Yuasa, S. Tanaka, H. Sawa, M. Miura, A. Matsui, H. Higashi, M. Musashi, K. Iwabuchi, M. Suzuki, et al. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse PNAS, January 22, 2008; 105(3): 1003 - 1008. [Abstract] [Full Text] [PDF] Y. Ke, E. E. Zhang, K. Hagihara, D. Wu, Y. Pang, R. Klein, T. Curran, B. Ranscht, and G.-S. Feng Deletion of Shp2 in the Brain Leads to Defective Proliferation and Differentiation in Neural Stem Cells and Early Postnatal Lethality Mol. Cell. Biol., October 1, 2007; 27(19): 6706 - 6717. [Abstract] [Full Text] [PDF] Y. Zhang, E. Diaz-Flores, G. Li, Z. Wang, Z. Kang, E. Haviernikova, S. Rowe, C.-K. Qu, W. Tse, K. M. Shannon, et al. Abnormal hematopoiesis in Gab2 mutant mice Blood, July 1, 2007; 110(1): 116 - 124. [Abstract] [Full Text] [PDF] R. J. Chan and G.-S. Feng PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase Blood, February 1, 2007; 109(3): 862 - 867. [Abstract] [Full Text] [PDF] J. Chen, W.-M. Yu, H. Daino, H. E. Broxmeyer, B. J. Druker, and C.-K. Qu SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl Blood, January 15, 2007; 109(2): 778 - 785. [Abstract] [Full Text] [PDF] T. V. Nguyen, Y. Ke, E. E. Zhang, and G.-S. Feng Conditional Deletion of Shp2 Tyrosine Phosphatase in Thymocytes Suppresses Both Pre-TCR and TCR Signals J. Immunol., November 1, 2006; 177(9): 5990 - 5996. [Abstract] [Full Text] [PDF] W.-M. Yu, H. Daino, J. Chen, K. D. Bunting, and C.-K. Qu Effects of a Leukemia-associated Gain-of-Function Mutation of SHP-2 Phosphatase on Interleukin-3 Signaling J. Biol. Chem., March 3, 2006; 281(9): 5426 - 5434. [Abstract] [Full Text] [PDF] G.-M. Zou, R. J. Chan, W. C. Shelley, and M. C. Yoder Reduction of Shp-2 Expression by Small Interfering RNA Reduces Murine Embryonic Stem Cell-Derived In Vitro Hematopoietic Differentiation Stem Cells, March 1, 2006; 24(3): 587 - 594. [Abstract] [Full Text] [PDF] L. Yuan, W.-M. Yu, M. Xu, and C.-K. Qu SHP-2 Phosphatase Regulates DNA Damage-induced Apoptosis and G2/M Arrest in Catalytically Dependent and Independent Manners, Respectively J. Biol. Chem., December 30, 2005; 280(52): 42701 - 42706. [Abstract] [Full Text] [PDF] R. J. Salmond, G. Huyer, A. Kotsoni, L. Clements, and D. R. Alexander The src Homology 2 Domain-Containing Tyrosine Phosphatase 2 Regulates Primary T-Dependent Immune Responses and Th Cell Differentiation J. Immunol., November 15, 2005; 175(10): 6498 - 6508. [Abstract] [Full Text] [PDF] R. Xu, Y. Yu, S. Zheng, X. Zhao, Q. Dong, Z. He, Y. Liang, Q. Lu, Y. Fang, X. Gan, et al. Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia Blood, November 1, 2005; 106(9): 3142 - 3149. [Abstract] [Full Text] [PDF] M. Tartaglia, S. Martinelli, G. Cazzaniga, V. Cordeddu, I. Iavarone, M. Spinelli, C. Palmi, C. Carta, A. Pession, M. Arico, et al. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia Blood, July 15, 2004; 104(2): 307 - 313. [Abstract] [Full Text] [PDF] M. L. Loh, S. Vattikuti, S. Schubbert, M. G. Reynolds, E. Carlson, K. H. Lieuw, J. W. Cheng, C. M. Lee, D. Stokoe, J. M. Bonifas, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis Blood, March 15, 2004; 103(6): 2325 - 2331. [Abstract] [Full Text] [PDF] L. M. Thai, L. K. Ashman, S. N. Harbour, P. M. Hogarth, and D. E. Jackson Physical proximity and functional interplay of PECAM-1 with the Fc receptor Fc{gamma}RIIa on the platelet plasma membrane Blood, November 15, 2003; 102(10): 3637 - 3645. [Abstract] [Full Text] [PDF] R. Zhao, X. Fu, L. Teng, Q. Li, and Z. J. Zhao Blocking the Function of Tyrosine Phosphatase SHP-2 by Targeting Its Src Homology 2 Domains J. Biol. Chem., October 31, 2003; 278(44): 42893 - 42898. [Abstract] [Full Text] [PDF] S.-i. Yusa and K. S. Campbell Src Homology Region 2-Containing Protein Tyrosine Phosphatase-2 (SHP-2) Can Play a Direct Role in the Inhibitory Function of Killer Cell Ig-Like Receptors in Human NK Cells J. Immunol., May 1, 2003; 170(9): 4539 - 4547. [Abstract] [Full Text] [PDF] E. Asante-Appiah and B. P. Kennedy Protein tyrosine phosphatases: the quest for negative regulators of insulin action Am J Physiol Endocrinol Metab, April 1, 2003; 284(4): E663 - E670. [Abstract] [Full Text] [PDF] W.-M. Yu, T. S. Hawley, R. G. Hawley, and C.-K. Qu Role of the docking protein Gab2 in beta 1-integrin signaling pathway-mediated hematopoietic cell adhesion and migration Blood, April 1, 2002; 99(7): 2351 - 2359. [Abstract] [Full Text] [PDF] E. Lelievre, H. Plun-Favreau, S. Chevalier, J. Froger, C. Guillet, G. C. A. Elson, J.-F. Gauchat, and H. Gascan Signaling Pathways Recruited by the Cardiotrophin-like Cytokine/Cytokine-like Factor-1 Composite Cytokine. SPECIFIC REQUIREMENT OF THE MEMBRANE-BOUND FORM OF CILIARY NEUROTROPHIC FACTOR RECEPTOR alpha COMPONENT J. Biol. Chem., June 15, 2001; 276(25): 22476 - 22484. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Qu, C.-K. Articles by Feng, G.-S. Search for Related Content PubMed PubMed Citation Articles by Qu, C.-K. Articles by Feng, G.-S. Related Collections Hematopoiesis and Stem Cells Immunobiology Signal Transduction Social Bookmarking                   What's this?

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020